Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study
Rheumatology International · 2020-12 · 40 (12) · 1987-1995
DOI: 10.1007/s00296-020-04660-y ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Rheumatology International, online erschienen am 29.07.2020. Verfasst von Sadao Jinno und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-chou, Kobe, Hyogo, 650-0017, Japan. s…. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: AbbVie, Asahi Kasei Pharma Corporation, Chugai Pharmaceutical.
Abstract (Originalsprache)
The objective of the study was to compare the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) patients. Patients with rheumatoid arthritis (RA) aged ≧18 years enrolled in a Japanese multicenter observational registry between 2009 and 2018 who had moderate or high disease activity when initiating bDMARDs were included. EORA was defined as RA with onset at 60 or over. After propensity score weighting for differences in confounding factors, generalized estimating equations were used to assess the relationship between the age of RA onset and bDMARD clinical effectiveness at 48 weeks after starting a bDMARD. Among a total of 7183 patients in the registry, 2815 (39.2%) were identified as EORA. The proportion of patients on bDMARDs was lower in the EORA as compared to the YORA (18.3% vs 28.0%, p < 0.001). Of the 989 bDMARD initiators, 364 (36.8%) were identified as EORA. The median follow-up duration was 48 weeks both in the EORA and in the YORA. After adjusting for differences in baseline characteristics between the two age groups, there was no significant difference in Clinical Disease Activity Index scores at 48 weeks (mean difference 1.01, 95% CI = - 0.62 to 2.64, p = 0.22). There was a non-significant trend toward lower remission in EORA (OR = 0.52, 95% CI = 0.24-1.14, p = 0.10), and low disease activity/remission was similar (OR = 0.86, 95% CI = 0.29-2.52, p = 0.77). Drug retention (HR = 0.95, 95% CI = 0.55-1.35, p = 0.78) and discontinuations due to adverse events (HR = 0.78, 95% CI = 0.38-1.18, p = 0.22) were similar between the two age groups after adjustment for confounders. In RA patients initiating bDMARDs, improvements in clinical disease at 48 weeks were similar between EORA and YORA. Drug retention and adverse events discontinuation were similar between the two age groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-chou, Kobe, Hyogo, 650-0017, Japan. sadaoj@gmail.com.
- Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-chou, Kobe, Hyogo, 650-0017, Japan.
- Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
- VA Boston Healthcare System, Boston, MA, USA.
- Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan.
Förderung
- AbbVie
- Asahi Kasei Pharma Corporation
- Chugai Pharmaceutical
- Eisai
- Janssen Pharmaceuticals
- Ono Pharmaceutical
- Sanofi
- Center for Information Technology
Zitieren
APA
Jinno, S., Onishi, A., Dubreuil, M., Akashi, K., Hashimoto, M., Yamamoto, W., Murata, K., Takeuchi, T., Kotani, T., Maeda, Y., Ebina, K., Son, Y., Amuro, H., Hara, R., Katayama, M., Saegusa, J., & Morinobu, A. (2020). Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study. Rheumatology International, 40(12), 1987-1995. https://doi.org/10.1007/s00296-020-04660-y
Vancouver
Jinno S, Onishi A, Dubreuil M, Akashi K, Hashimoto M, Yamamoto W, et al. Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study. Rheumatology International. 2020;40(12):1987-1995. doi:10.1007/s00296-020-04660-y
BibTeX
@article{Jinno2020,
author = {Jinno, Sadao and Onishi, Akira and Dubreuil, Maureen and Akashi, Kengo and Hashimoto, Motomu and Yamamoto, Wataru and Murata, Koichi and Takeuchi, Tohru and Kotani, Takuya and Maeda, Yuichi and Ebina, Kosuke and Son, Yonsu and Amuro, Hideki and Hara, Ryota and Katayama, Masaki and Saegusa, Jun and Morinobu, Akio},
title = {Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study},
journal = {Rheumatology International},
year = {2020},
volume = {40},
number = {12},
pages = {1987--1995},
doi = {10.1007/s00296-020-04660-y}
}
EUVIMED